Trial of AMB-05X for Patients with ctDNA(+) Colorectal Cancer After Curative-intent Treatment
This is a Phase II trial to study the efficacy of AMB-05X in patients with CRC MRD as determined by a ctDNA(+) blood test and no clinically detectable radiographic disease.
Key Eligibility Criteria
- Diagnosis of any stage (I-IV) colorectal adenocarcinoma
- Completion of all curative-intent treatments
- No evidence of measurable disease on imaging or clinically detectable disease at least 28 days after completion of all treatment
- Positive ctDNA test result (Signatera) at least 28 days after completion of all treatment
Visit and Treatment Details
This is a single group assignment in which participants will be treated every two weeks for six months, followed by surveillance for an average of one year.
